Incyte Genomics is scheduled to present at several healthcare conferences, including JP Morgan's 43rd Annual Healthcare Conference in January and Citi's 2024 Global Healthcare Conference. Results from Q3 earnings revealed missed estimates despite a considerable 19.6% stock gain in three months. Furthermore, their late-stage NSCLC study surpassed primary and secondary objectives, and the stock surged by 2.1% post last earnings report. A strategic move saw the issuance of stock options and RSUs to 27 new hires. Despite this, there were hiccups with halting a significant drug trial due to safety concerns and discontinuing another program. Despite a minor 0.9% surge since the last earnings report, Incyte's stock has suffered a drastic 29.6% fall year-to-date. Despite these challenges, Incyte has prepared to present new and promising data on an Oncology candidate at ESMO and Phase 3 Lymphoma Trial Data at the ASH meeting. They have also been named as one of the top 5 companies on Science Magazine's 2024 top employers list.
Incyte Genomics INCY News Analytics from Thu, 05 Mar 2015 08:00:00 GMT to Tue, 17 Dec 2024 08:00:00 GMT -
Rating 0
- Innovation 7
- Information 5
- Rumor -7
